aceclidine
Trade name: Vizz
Small moleculeapproved
Approved
Jul 31, 2025
Clinical trial activity
10 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
8
Phase 3
4
Phase 4
0
Earliest trial started Sep 1, 2015 (NCT02554396)
Timeline
2010s
- Jan 1, 2015
Presbyopia Therapies, LLC — Earliest Phase 2 Sponsor(trial)
2020s
- Jan 1, 2022
Presbyopia Therapies, LLC — Earliest Phase 3 Sponsor(trial)
- Jan 1, 2023
Presbyopia Therapies, LLC — Earliest Phase 1 Sponsor(trial)
- Jul 31, 2025
Earliest FDA Approval
- Jul 31, 2025
Presbyopia Therapies, LLC — Marketing Organization
Indications
Approved for
Mechanism of action
Muscarinic acetylcholine receptor agonist
- Muscarinic acetylcholine receptor M3 (CHRM3) ↗
- Muscarinic acetylcholine receptor M4 (CHRM4) ↗
- Muscarinic acetylcholine receptor M1 (CHRM1) ↗
- Muscarinic acetylcholine receptor M5 (CHRM5) ↗
- Muscarinic acetylcholine receptor M2 (CHRM2) ↗
- Muscarinic acetylcholine receptor M2
- Muscarinic acetylcholine receptor M1
- Muscarinic acetylcholine receptor M4
- Muscarinic acetylcholine receptor M5
- Muscarinic acetylcholine receptor M3
- Muscarinic acetylcholine receptors; M2 & M3
- Muscarinic acetylcholine receptors; M1 & M2
- Muscarinic acetylcholine receptor M1/M5 chimeric protein
- Muscarinic acetylcholine receptor M1 and M3
- Muscarinic acetylcholine receptor M2 and M4
- Muscarinic acetylcholine receptor M2 and M5
Approval history
- approvedJul 31, 2025
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)OC1CN2CCC1CC2- Mol. weight
- 169.22 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL20835 ↗
Also known as
- 3-quinuclidinol acetate
- 3-quinuclidinyl acetate
- aceclidin
- aceclidine
- aceclidine
- aceclidine hcl
- aceclidine hydrochloride
- aceclidine hydrochloride
- aceclidine hydrochloride
- aceclidine hydrochloride
- prx-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06270030 | Phase 1 | Mar 4, 2024 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Presbyopia Therapies, LLC |
| NCT06045299 | Phase 3 | Sep 27, 2023 | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Presbyopia Therapies, LLC |
| NCT05936489 | Phase 1 | Jul 6, 2023 | ORA, Inc., Presbyopia Therapies, LLC |
| NCT05728944 | Phase 3 | Apr 24, 2023 | ORA, Inc., Presbyopia Therapies, LLC |
| NCT05753189 | Phase 3 | Feb 21, 2023 | ORA, Inc., Presbyopia Therapies, LLC |
| NCT05656027 | Phase 3 | Dec 19, 2022 | ORA, Inc., Presbyopia Therapies, LLC |
| NCT05431543 | Phase 2 | Aug 6, 2022 | ORA, Inc., Presbyopia Therapies, LLC |
| NCT05294328 | Phase 2 | May 5, 2022 | ORA, Inc., Presbyopia Therapies, LLC |
| NCT03201562 | Phase 2 | Apr 30, 2017 | Presbyopia Therapies, LLC |
| NCT02554396 | Phase 2 | Sep 1, 2015 | Presbyopia Therapies, LLC |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Presbyopia Therapies, LLC | For profit | 10 | 8 | 3 | 2015 |
| ORA, Inc. | For profit | 6 | 0 | 3 | 2022 |
| Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | For profit | 2 | 2 | 2 | 2023 |
3 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Presbyopia Therapies, LLC | For profit | MKTG | Jul 31, 2025 |